

Haematologica
HAEMATOL/2016/146076
Version 4

Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bortezomib and dexamethasone

Ana-Alicia López-Iglesias, Lorena González-Méndez, Laura San-Segundo, Ana B. Herrero, Susana Hernández-García, Montserrat Martín-Sánchez, Norma C. Gutiérrez, Teresa Paíno, Pablo Avilés, María-Victoria Mateos, Jesús F. San-Miguel, Mercedes Garayoa, and Enrique M. Ocio

Disclosures: Acknowledgements This work was in part funded by the Spanish ISCIII-FIS (PI 15/0067 and PI15/02156) and FEDER, the Spanish RTICC (RD12/0036/0058), "Asociación Española Contra el Cancer" (AECC, GCB120981SAN), the regional Council from "Castilla y Leon" (GRS 1175/A/15 and FIC335U14) and a research grant from Pharmamar SAU. MMS were also supported by the Network of Centers for Regenerative Medicine and Cellular Therapy from Castilla y León, Spain. A-A López-Iglesias was supported by a grant from the Spanish Society of Hematology and Hemotherapy. Disclosure of Potential Conflicts of Interest: EMO, MVM and JFSM disclose honoraria from Pharmamar SAU. PA is employee for Pharmamar SAU.

Contributions: EMO, MG, TP and AALI designed research and wrote the paper. LGM, AALI, TP, SHG, ABH and MMS performed experiments and analyzed the data. MVM, NCG, EMO and JFSM provided clinical samples and contributed to the clinical data. All authors reviewed and approved the manuscript.